Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC using its next-generation solvent-free manufacturing process. This milestone supports the product’s planned commercial launch in Europe and marks a significant advancement in production efficiency. The new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC, which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.
The approval comes as Regentis prepares to address a significant unmet need in cartilage repair. The company notes that approximately 470,000 cases for cartilage knee repair occur annually in the U.S., where no off-the-shelf treatment is available. GelrinC aims to fill this gap by providing a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. The Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. With the new manufacturing process, Regentis expects to scale production efficiently to meet anticipated demand in Europe and eventually the U.S.
The company’s focus on orthopedic treatments positions it well in a growing market. The U.S. cartilage repair market alone is valued at approximately $3 billion, and Regentis aims to capture a significant share with GelrinC. The European approval for the manufacturing process is a critical step toward commercialization, and the company is actively expanding its network of Centers of Excellence and training programs for surgeons.
For more information, the full press release is available at https://ibn.fm/Ths4h. The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT.
